General Information of Drug (ID: DM2I91C)

Drug Name
7-(3-Hydroxy-phenyl)-naphthalen-2-ol Drug Info
Synonyms 7-(3-hydroxyphenyl)-2-naphthol
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
10171410
TTD Drug ID
DM2I91C

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
NARINGENIN DMHAZLM N. A. N. A. Phase 1 [3]
Nicotinamide-Adenine-Dinucleotide DM9LRKB N. A. N. A. Investigative [4]
2'-Monophosphoadenosine 5'-Diphosphoribose DME9S8M Discovery agent N.A. Investigative [4]
APIGENIN DMI3491 Discovery agent N.A. Investigative [3]
KAEMPFEROL DMHEMUB Discovery agent N.A. Investigative [3]
4-ANDROSTENE-3-17-DIONE DMSE8NU Discovery agent N.A. Investigative [4]
6-(3-Hydroxy-phenyl)-naphthalen-2-ol DMH8WA2 Discovery agent N.A. Investigative [5]
NSC-94258 DM6VY3P Discovery agent N.A. Investigative [3]
4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol DM7ERYJ Discovery agent N.A. Investigative [6]
6-(4-Hydroxy-phenyl)-naphthalen-1-ol DM2V9XI Discovery agent N.A. Investigative [2]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Conjugated Estrogens DMLT0E1 Dyspareunia GA12 Approved [7]
Trilostane DMQZ9GF Cushing disease 5A70 Approved [8]
ARZOXIFENE DMOKCVI Breast cancer 2C60-2C65 Approved [9]
Estrogen DMGY0UT Menopause symptom GA30.0 Approved [10]
MF-101 DM8Z0I3 Hepatitis virus infection 1E50-1E51 Phase 3 [11]
Genistein DM0JETC Menopause symptom GA30.0 Phase 2/3 [12]
AUS-131 DMUXO3Z Hot flushes GA30 Phase 2 [13]
ERB-041 DMCEPUA Inflammatory bowel disease DD72 Phase 2 [14]
Erteberel DMU1XZD Prostate hyperplasia GA90 Phase 2 [15]
VG-101 DMAN21O Menopause symptom GA30.0 Phase 1/2 [16]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Estrogen receptor (ESR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [17]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [18]
Estrone DM5T6US Acne vulgaris ED80 Approved [18]
Estradiol Valerate DM8MC6O Hormone replacement therapy 8E01 Approved [8]
Estradiol Acetate DM07U2A Hormone replacement therapy 8E01 Approved [8]
Estradiol Cypionate DM27Z5T Hormone replacement therapy 8E01 Approved [8]
Ethinyl Estradiol DMODJ40 Acne vulgaris ED80 Approved [19]
Raloxifene DMDKF3M Osteoporosis FB83.0 Approved [20]
Ospemifene DMC4GEI Dyspareunia GA12 Approved [21]
Toremifene DMQYUWG Breast cancer 2C60-2C65 Approved [22]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) TTIWB6L DHB1_HUMAN Inhibitor [2]
Estrogen receptor (ESR) TTZAYWL ESR1_HUMAN Inhibitor [1]
Estrogen receptor beta (ESR2) TTOM3J0 ESR2_HUMAN Inhibitor [1]

References

1 ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79.
2 Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors... J Med Chem. 2008 Apr 10;51(7):2158-69.
3 Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries. J Med Chem. 2008 Jul 24;51(14):4188-99.
4 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
5 Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design,... J Med Chem. 2008 Aug 14;51(15):4685-98.
6 New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
7 Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination. Mol Endocrinol. 2009 Jan;23(1):74-85.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9 Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity. J Med Chem. 2007 May 31;50(11):2682-92.
10 Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15133-6.
11 MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial. Menopause. 2009 May-Jun;16(3):458-65.
12 Company report (Axcentua)
13 S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr. 2005 May;81(5):1072-9.
14 Erb-041, an estrogen receptor-beta agonist, inhibits skin photocarcinogenesis in SKH-1 hairless mice by downregulating the WNT signaling pathway. Cancer Prev Res (Phila). 2014 Feb;7(2):186-98.
15 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031986)
16 Update on alternative therapies for vulvovaginal atrophy. Patient Prefer Adherence. 2011; 5: 533-536.
17 Modulators of vascular sex hormone receptors and their effects in estrogen-deficiency states associated with menopause. Recent Pat Cardiovasc Drug Discov. 2008 Nov;3(3):165-86.
18 Reprint of Are all estrogens the same Maturitas. 2008 Sep-Oct;61(1-2):195-201.
19 17alpha-Ethinylestradiol hinders nucleotide excision repair in zebrafish liver cells. Aquat Toxicol. 2009 Dec 13;95(4):273-8.
20 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).
21 Clinical pipeline report, company report or official report of Shionogi (2011).
22 Effect of selective estrogen receptor modulators on cell proliferation and estrogen receptor activities in normal human prostate stromal and epithe... Prostate Cancer Prostatic Dis. 2009;12(4):375-81.